Année d’arrivée au Centre
1997
Formation
- DES d’hématologie clinique 1997 Rouen
- Master de biologie cellulaire 2007 Rouen
- DU infectiologie en hématologie 2002 Créteil Master de physiologie 1993 Rouen
Interventions pratiquées ou expertise
- SFH
- EHA
- ASH
Sociétés savantes
- FILO (conseil scientifique)
- GRAALL (comité d’administration et conseil scientifique)
- LYSA (membre)
Publications majeures
- Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia. 2003 Nov;17(11):2220-4
- Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2016 Feb 20;34(6):572-80. doi: 10.1200/JCO.2015.61.5385. Epub 2015 Dec 7. PubMed PMID: 26644537.
- Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators. Hematol. 2017 Jul;51:7-16. doi: 10.1016/j.exphem.2017.04.002. Epub 2017 Apr 12. Review. PubMed PMID: 28412288.
- Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-study.
Blood. 2008 Feb 1;111(3):1094-100. Epub 2007 Nov 14 - High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.
Br J Haematol. 2008 Sep;143(1):54-9 - ¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies. Anticancer Res. 2015 May;35(5):2999-3005. PubMed PMID: 25964587.
- Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15
J Clin Oncol. 2016 Feb 20;34(6):572-80. doi: 10.1200/JCO.2015.61.5385. Epub 2015 Dec 7. PubMed PMID: 26644537. - Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. Haematologica. 2018 Aug;103(8):e356-e359. doi: 10.3324/haematol.2017.182352. Epub 2018 Mar 8